期刊文献+

高通量透析对维持性血透患者血脂代谢的影响 被引量:4

下载PDF
导出
摘要 目的:探讨高通量透析(HPD)对MHD患者血脂代谢的影响。方法:将60例MHD患者分为研究组和对照组,研究组30例采用高通量血液透析治疗,对照组30例采用低通量血液透析治疗,观察两组患者血脂变化情况。结果:两组患者的血清肌酐(BUN)、血尿素氮(Cr)水平比较,差异无统计学意义(P>0.05);研究组患者血浆胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL)和脂蛋白A(Apo-A)均显著低于对照组,而高密度脂蛋白(HDL)显著高于对照组,差异有统计学意义(P<0.05)。结论:高通量透析能有效改善MHD患者的血脂代谢。
作者 叶红波
出处 《吉林医学》 CAS 2013年第12期2251-2252,共2页 Jilin Medical Journal
  • 相关文献

参考文献5

二级参考文献19

  • 1陈欣,季大玺.高通量血液透析[J].肾脏病与透析肾移植杂志,2005,14(1):78-81. 被引量:67
  • 2刘宏宝,陈威,王汉民,张鹏,许国双,白淑蓉,孙世仁,刘晓渭.高通量血液透析在慢性肾衰竭患者治疗中的综合评价[J].中国血液净化,2007,6(5):253-256. 被引量:28
  • 3George A. The microinflammatory state in uremia: cause and potential consequenees[J].J Am Soc Nephrol, 2001,12, 12: 1549-1557.
  • 4Otsubo Y, Uchiday, Yasumoto Y, etal. ApoC III is a potent factor on lipid abnormalities in hemodialysis patients [J]. J Am Soc Nephrol, 1993,4:375(abstract).
  • 5Axelsson J, Bergsten A, Qureshi AR, etal. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance[J].Kidney Inl, 2006,69, 69:596-604.
  • 6王海燕.肾脏病学[M].北京:人民卫生出版社,2009:831-834.
  • 7Ansell BJ.Hyperlipidaemia and cardiovascular disease[J].Curr Opin Lipidol,2008,19(4):433.
  • 8George A.The microinflammtory state in uremia:cause and potential consequences[J].J Am Soc Nephrol,2001,12,12:1549.
  • 9Eisenberg S,Heiss G,Friedlander Y et al Comparison of plasma lipid,lipoproteins and dyslipoproteinemia in Israel and United States[J].Atherosclerosis,1986,59:63.
  • 10Merello Godino JI,Rentero R,Orlandini G,et al.Rescult from euclid(european clinical dialysis database):impact of shifting of treatment modality[J].Int J Artif Organs,2002,25(11):1049.

共引文献70

同被引文献49

  • 1吴平勇,张庆红,张建鄂,李涛,张永,王顺华,李新华.高通量透析可改善维持性血液透析患者肾性贫血[J].生物医学工程与临床,2005,9(1):40-44. 被引量:9
  • 2耿杰.尿毒症血液透析血清脂质变化的分析[J].中国航天工业医药,1999,1(1):32-33. 被引量:3
  • 3许传文.高通量透析对血β_2微球蛋白浓度及蛋白质浓度的影响[J].临床内科杂志,2005,22(6):424-425. 被引量:1
  • 4Eknoyan G, Beck G J, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis [ J ]. N Engl J Med, 2002, 347 (25) : 2010-2019.
  • 5Malyszko JS, Malyszko J, Hryszko T, et al. Markers of endothelial damage in patients on hemodialysis and hemodiafiltration [ J ]. J Nephrol, 2006, 19(2): 150-154.
  • 6Raggi P, Vukicevic S, Moyses RM, et al. Ten-year experience with sevelamer and calcium salts as phosphate binders [ J ]. Clin J Am Soc Nephrol, 2010, 5 (Suppl 1 ) : $31-$40.
  • 7Penne EL, van der Weerd NC, Grooteman MP, et al. Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients [ J ]. Clin J Am Soe Nephrol, 2011, 6(2) : 281-289.
  • 8Kong X, Zhang L, Zhang L, et al. Mineral and bone disorder in Chinese dialysis patients: a muhicenter study [ J ]. BMC Nephrology, 2012, 13 : 116.
  • 9Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population [ J ]. Nephrol Dial Transplant, 2011, 26 ( 6 ) : 1948- 1955.
  • 10Shidara K, Inaba M, Okuno S, et al. Influence of nutritional status on serum large N-truncated PTH, but not PTH (1-84) in hemodialysis patients [ ]]. Biomed Pharmacother, 2007,61 (2/3) : 142-147.

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部